On 22 October 2007, orphan designation (EU/3/07/496) was granted by the European Commission to Only for Children Pharmaceuticals, France, for mercaptopurine (oral liquid) for the treatment of acute lymphoblastic leukaemia.
The sponsorship was transferred to Orbona Pharma Ltd, United Kingdom, in October 2013.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Treatment of acute lymphoblastic leukaemia
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: